Average Co-Inventor Count = 7.80
ph-index = 3
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. Array Biopharma Inc. (10 from 329 patents)
2. Eli Lilly and Company (4 from 4,443 patents)
14 patents:
1. 12171739 - N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases
2. 10780073 - N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases
3. 9809590 - Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors
4. 9693989 - N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases
5. 9174981 - Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors
6. 8987251 - Triazolopyridine compounds as PIM kinase inhibitors
7. 8895550 - Triazolopyridine compounds as PIM kinase inhibitors
8. 8841455 - Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as cFMS inhibitors
9. 8575145 - Triazolopyridine compounds as PIM kinase inhibitors
10. 8557809 - Triazolopyridine compounds as PIM kinase inhibitors
11. 7816523 - Potentiators of glutamate receptors
12. 7803938 - Potentiators of glutamate receptors
13. 7678794 - Potentiators of glutamate receptors
14. 7598423 - Potentiators of glutamate receptors